Ultragenyx Pharmaceutical vs TG Therapeutics
RARE and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RARE and TGTX compare
TG Therapeutics is the larger company, worth 5.9 times as much as Ultragenyx Pharmaceutical ($9.4B against $1.6B).
TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 17.5% for Ultragenyx Pharmaceutical).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −81.7% at Ultragenyx Pharmaceutical.
TG Therapeutics scores higher on the StockData Score (10 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RARE | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $9.4B |
| Share price | $16.10 | $61.18 |
| Change, 1 year | −53.5% | 81.1% |
| Change, 5 years | −80.7% | 72.3% |
| Beta (5Y) | 1.07 | 1.73 |
| Employees | 1,371 | 399 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.3× |
| P/S | 2.2× (better) | 11.7× |
| P/B | – | 15.5× |
| EV/EBITDA | – | 69.6× |
| P/FCF | – | 539× |
| FCF yield | −30.8% | 0.19% (better) |
| Fair value | – | $76.21 |
| Margin of safety | – | 19.7% |
| Growth | ||
| Revenue growth (TTM) | 17.5% | 76.1% (better) |
| Revenue growth, 5Y average | 19.9% | 427% (better) |
| Net income growth (TTM) | – | 630% |
| EPS growth (TTM) | – | 641% |
| Profitability | ||
| Gross margin | – | 82.4% |
| Operating margin | −73.6% | 17.1% (better) |
| Net margin | −81.7% | 55.2% (better) |
| FCF margin | −68.2% | 2.2% (better) |
| Return on equity | – | 100% |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 1.23 |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | – | 3.6× |
| Current ratio | 1.73 | 4.27 (better) |
| Altman Z-score | −5.28 | 5.93 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.9% |
| Shareholder yield | 0.00% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 108% | 72.6% |
| Held by insiders | 4.0% | 16.1% |
| Insider net buying, 12 months | −$3.7M | −$438K (better) |
| Short interest, % of float | 21.5% | 23.8% |
Go deeper
- RARE stock overview
- RARE income statement
- RARE valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.